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The recently discovered angiotensin-converting enzyme-related carboxypep-
tidase 2 (ACE2)-[Angiotensin-(1-7)(Ang-(1-7)]-Mas receptor axis has an opposing 
function to that of the ACE-Angiotensin II (Ang II)-Angiotensin type 1 (AT1) 
receptor axis. Ang-(1-7) is present in the kidneys at concentrations comparable 
to those of Ang II and is associated with vasodilation, modulation of sodium 
and water transport, and stimulation of nitric oxide (NO) synthase. Ang-(1-7) 
also acts as a physiological antagonist of Ang II by counterbalancing the Ang II-
mediated intracellular signaling pathway. In a hypertensive model, increased ACE 
and decreased ACE2 along with a higher ACE/ACE2 ratio in hypertensive kidneys 
appeared to favor Ang II generation, leading to hypertensive renal damage. In 
addition, the administration of a selective Ang-(1-7) receptor blocker or an ACE2 
inhibitor was associated with worsening of hypertension and renal function. Ang-
(1-7)-mediated increases in renal blood flow were abolished by blockade of the 
Mas receptor and by inhibition of prostaglandin release and NO in spontaneously 
hypertensive rats and in Wistar-Kyoto controls. Further research on the function 
of the ACE2-Ang-(1-7)-Mas receptor axis could lead to a novel target for 
inhibiting kidney disease progression.
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(ACE)-Ang II-AT1 receptor axis has important physiologic 
and pathologic roles. However, the recent discovery of 
ACE-related carboxypeptidase (ACE2) and angiotensin 1-7 
(Ang-(1-7)) has changed the way in which the RAS is viewed 
(Fig. 1). Ang-(1-7) is present in the kidneys at concentrations 
comparable to those of Ang II and is associated with 
vasodilation, modulation of sodium and water transport, 
and stimulation of nitric oxide (NO) synthase
1-3).
ACE2 and Ang-(1-7)
ACE2 is a type 1 integral membrane glycoprotein that is 
Introduction
The renin-angiotensin system (RAS) is a pivotal mediator 
of renal and vascular homeostasis. Its systemic actions 
include the regulation of blood pressure, natriuresis, and 
blood volume control. The RAS also plays an important 
role at a local level, regulating regional blood flow and 
controlling trophic and fibrotic responses to a range of 
stimuli. The RAS is composed of a number of different 
regulatory components and effector molecules. Angiotensin 
II (Ang II) acts by binding to Ang II type 1 (AT1) and Ang II 
type 2 (AT2) receptors. The angiotensin-converting enzyme 42      JY Moon • ACE2 and Angiotensin-(1-7) in Hypertensive Renal Disease
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found in most tissues, with its highest expression observed 
in the kidneys, endothelium, and heart
4, 5). The extracellular 
surface of the ACE2 enzyme contains a single catalytic 
metallopeptidase domain that shares 42% sequence identity 
and 61% sequence similarity with the N-terminal catalytic 
domain of somatic ACE. ACE2 is an exopeptidase that 
catalyzes the conversion of Ang I to the nonapeptide Ang-
(1-9) and the conversion of Ang II to the heptapeptide Ang-
(1-7). The primary role of ACE2 is converting Ang II into 
Ang-(1-7) with an efficacy > 400-fold greater than that of 
the hydrolytic action of ACE2 in forming Ang-(1-9)
6). ACE2 
is associated with a reduction in Ang II and an increase 
in Ang-(1-7) levels. ACE2 protein levels are significantly 
decreased in the kidneys of hypertensive patients, and 
patients with late diabetic nephropathy
7, 8). 
The heptapeptide Ang-(1-7), generated from either Ang I 
or Ang II, acts by opposing the vasoconstrictor, proliferative, 
and profibrotic actions of Ang II in the circulation and in 
cardiac, vascular, and renal tissues
9, 10). In a type 2 diabetic 
animal model, Ang-(1-7) attenuated Ang II-mediated 
NAD(P)H oxidase activation and reactive oxygen species 
production in diabetic glomeruli and mesangial cells were 
noted
11). Ang-(1-7) also binds to the Mas receptor, a seven 
transmembrane protein with domains containing sequences 
characteristic of G-protein coupled receptors. The Mas 
receptor is expressed in renal proximal tubular cells, 
afferent arterioles, cardiac myocytes, and neuronal cells. It 
conveys Ang-(1-7) signals via transcriptional factors.
Effects of ACEI and angiotensin II receptor blockers 
(ARBs) partly depend on ACE2 and Ang-(1-7)
ACE inhibitors and receptor blockers can affect the 
ACE2-Ang-(1-7) system. ACE inhibitors increase the 
production of Ang I, which is converted to Ang-(1-7) by 
ACE2, and endopeptidase. The antihypertensive actions 
of ACE inhibition are obtained by increased excretion of 
Ang-(1-7), which was observed in urine samples of patients 
with essential hypertension whose blood pressure was 
controlled by 6 months of treatment with captopril
12). 
Blockade of AT1 receptors may be particularly important 
because the increase in the concentration of Ang II will 
stimulate greater production of Ang-(1-7). In addition, the 
low affinity binding of Ang-(1-7) to the AT1 receptor may 
allow the peptide to act as an antagonist in the presence 
of Ang II. ARB and olmesartan-treated spontaneously 
hypertensive rats (SHR) showed upregulation of ACE2 
mRNA in the aorta as well as plasma Ang-(1-7) levels, 
which was related to the selective reduction of the thoracic 
aorta media-to-lumen ratio and media thickness associated 
with olmesartan
13).
The ACE2-Ang-(1-7)-Mas receptor axis in 
hypertension: focus on the kidneys 
Numerous studies have documented the presence of 
RAS components in the kidneys, indicating that the kidney 
is a site at which an intrarenal system participates in the 
regulation of glomerular-tubular balance. ACE and ACE2 
are expressed in the renal proximal tubules, but inside the 
glomeruli, they are mainly expressed in the podocytes
14). 
In normal kidneys, high constitutive levels of ACE2 and a 
higher ACE2/ACE ratio may be associated with an increase 
in the Ang II breakdown system compared to Ang II 
generation, which may be important for maintaining the 
normal physiological and biological effects of Ang II. In 
contrast, increased ACE and decreased ACE2 with a higher 
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Fig. 1. Renin-Angiotensin-Aldosterone System. ACE2, angiotensin-
converting enzyme-related carboxypeptidase 2; ACE, angiotensin-
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ACE/ACE2 ratio in hypertensive kidneys may favor Ang II 
generation, leading to hypertensive cardiovascular and renal 
damage
15). Elevated Ang II induces ACE expression and 
downregulates ACE2 expression by HK-2 cells. Increased 
expression of cortical and medullary Ang II and cortical 
ACE2 activity was also found in a model of hypertension 
with increased tissue renin. In an experimental model of 
renal hypertension, the administration of a selective Ang-
(1-7) receptor blocker or an ACE2 inhibitor was associated 
with worsening of hypertension and renal function
16). Ang-
(1-7)-mediated increases in renal blood flow was abolished 
by blockade of the Mas receptor and by inhibition of 
prostaglandin release and nitric oxide in SHR and Wistar-
Kyoto (WKY) controls
3, 17, 18). 
The systemic vasodilator effects of Ang-(1-7) are not 
consistently observed in animals with an intact baroreceptor 
reflex, or in conditions where there is no activation of 
the endogenous RAS. In a type 2 diabetic animal model, 
exclusive Ang-(1-7) infusion did not result in any changes 
in blood pressure or microalbuminuria. Likewise, ACE2-
knockout mice showed mild elevation of blood pressure, 
but renal injury was minor. However, after acute Ang II 
infusion, plasma concentrations of Ang II increased and 
were almost 3-fold higher in ACE2-deficient mice than in 
controls. In a model of Ang II-dependent hypertension, 
blood pressure was substantially higher in ACE2-deficient 
mice compared with wild-type mice. The vascular response 
to Ang-(1-7) (and, by association, ACE2) was augmented 
in the following conditions: low salt diet; renin transgenic 
hypertensive rats; and Ang II infusion. In all of these con-
ditions, endogenous RAS was stimulated.
Sexual differences in blood pressure related to 
the ACE2-Ang-(1-7)-Mas axis
Male SHR have elevated blood pressure and a higher 
incidence of albuminuria compared to age-matched 
female SHR
19, 20). Treatment of male and female SHR with 
enalapril reduced blood pressure to similar levels in both 
sexes, indicating that both hypertension and sex differences 
in blood pressure are RAS mediated
21). There are known 
sex differences in the expression levels of RAS components, 
and in functional responses to Ang II infusion. Young 
male SHR have higher levels of AT1 mRNA and protein 
expression in the kidneys, aorta, and mesenteric arteries, 
while AT2 mRNA expression is higher in females
22). 
Sullivan et al. reported that Ang-(1-7) levels were greater in 
female compared with male SHR under basal conditions 
as well as following Ang II infusion, but Ang-(1-7) receptor 
antagonism abolished the sex differences in blood pressure 
response to Ang II infusion
23). In this study, A-779 resulted 
in an initial increase in blood pressure sensitivity to Ang II 
and in proteinuria, especially in females, suggesting that 
Ang-(1-7) antagonizes immediate Ang II-induced increases 
in blood pressure and renal injury. 
Conclusions
•	 ACE2	is	a	functional	component	of	the	RAS;	ACE2	
metabolizes	Ang	II	and	produces	Ang-(1-7),	thereby	
contributing	to	regulation	of	blood	pressure	and	progression	of	
renal	disease.
•	 Effects	of	ACEI	and	ARB	partly	depend	on	ACE2	activation.
•	 The	vascular	response	to	Ang-(1-7)	(and	by	association,	ACE2)	
is	augmented	in	conditions	where	the	endogenous	RAS	has	
been	stimulated.
•	 Sexual	differences	in	blood	pressure	are	associated	with	the	
ACE2-Ang-(1-7)-Mas	receptor	axis.
•	 Targeting	the	ACE2-Ang-(1-7)-Mas	receptor	axis	may	be	a	
novel	therapeutic	strategy	for	hypertension	and	diabetic	kidney	
disease.
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